Bone loss is not prevented by calcium and Vitamin D supplementation in postmenopausal breast cancer patients receiving aromatase inhibitors

We retrospectively analyzed 636 breast cancer patients underwent surgery at Ewha Womans University Mokdong Hospital (Seoul, Republic of Korea) between Jan. 2012 and Jun. 2018. All patients were postmenopausal, hormone receptor positive and received aromatase inhibitors as adjuvant therapy for 5 years. Patients receiving aromatase inhibitors as switching or extended therapy were excluded because prior SERM (Tamoxifen) could affect BMD change in the early period of aromatase inhibitors administration.